KPIs & Operating Metrics(New)
Biologics And Drug Delivery Revenue By CategoryBiologics And Drug Delivery Revenue By Category AnnualBreakdown Of AssetsCapital Equipment And Software Revenue By CategoryCapital Equipment And Software Revenue By Category AnnualCost Of RevenueDeferred RevenueEmployee StatisticsFunctional Neurosurgery Navigation And Therapy Revenue By CategoryFunctional Neurosurgery Navigation And Therapy Revenue By Category AnnualGross Margin %Gross ProfitOpex As A % Of Total Revenue %OPEX SegregationProfitabilityProfitability %Profitability AnnualProfitability Annual %Property And Equipment, Net BreakdownRemaining Performance ObligationsRemaining Performance Obligations AnnualRevenue By Business Vertical AnnualRevenue By Business Vertical Annual %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Revenue By Service LineRevenue By Service Line %Revenue By Service Line AnnualRevenue By Service Line Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

ClearPoint Neuro (CLPT) Gross Profit (2011 - 2026)

ClearPoint Neuro recorded quarterly Gross Profit of $7.8 million in Q1 2026, up 21.11% quarter-over-quarter from $6.4 million in Q4 2025, and up 51.13% year-over-year from $5.1 million in Q1 2025.

ClearPoint Neuro's Gross Profit history runs 15 years deep, the most recent figure standing at $7.8 million for Q1 2026.

  • In Q1 2026, Gross Profit rose 51.13% year-over-year to $7.8 million; the TTM figure through Mar 2026 stood at $25.3 million (up 28.32% YoY), while the FY2025 annual figure was $22.7 million, up 18.67% from the prior year.
  • Gross Profit came in at $7.8 million for Q1 2026 at ClearPoint Neuro, up from $6.4 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $7.8 million in Q1 2026 to a low of $3.1 million in Q2 2023.
  • A 5-year average of $4.5 million and a median of $4.5 million in 2024 frame the typical range for Gross Profit.
  • Across the five-year window, Gross Profit slipped 11.04% in 2023 and surged 59.56% in 2024, its largest moves.
  • ClearPoint Neuro's Gross Profit stood at $3.4 million in 2022, then increased by 19.22% to $4.0 million in 2023, then advanced by 18.66% to $4.8 million in 2024, then jumped by 34.48% to $6.4 million in 2025, then advanced by 21.11% to $7.8 million in 2026.
  • According to Business Quant data, Gross Profit over the past three periods registered $7.8 million, $6.4 million, and $5.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.